Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: An analysis of 166 cases

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 490-495

  Costa, Silvano ^a   Venturoli, Simona ^a   Negri, Giovanni ^b   Sideri, Mario ^c   Preti, Mario ^d   Pesaresi, Martina ^a   Falasca, Adriana ^a   Barbieri, Daniela ^a   Zerbini, Marialuisa ^a   Santini, Donatella ^a   Sandri, Maria Teresa ^c   Ghiringhello, Bruno ^d   Caroppo Venturini, Nadia ^c   Syrjänen, Stina ^e   Syrjänen, Kari ^f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^e UNIVERSITY OF TURKU   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adenocarcinoma in situ; Conservative treatment; Follow up, test performance; Predictive factors, PA GEE models

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; COLPOSCOPY; FEMALE; FEMALE GENITAL TRACT CYTOLOGY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL HYSTERECTOMY;

ADENOCARCINOMA; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONIZATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84856726295     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.039     Document Type: Article

References (30)

1. H.O. Smith, M.F. Tiffany, C.R. Qualls, and C.R. Key The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States. A 24-year population-based study Gynecol Oncol 78 2000 97 105
2. M.E. Sherman, S.S. Wang, J. Carreon, and S.S. Devesa Mortality trends for cervical squamous and adenocarcinoma in the United States Cancer 103 2005 1258 1264
3. D. Stockton, P. Cooper, and R.N. Lonsdale Changing incidence of invasive adenocarcinoma of the uterine cervix in East Anglia J Med Screen 4 1997 40 43
4. M. Zappa, C.B. Visioli, S. Ciatto, A. Iossa, E. Paci, and P. Sasieni Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence Br J Cancer 4 90 2004 1784 1786
5. P. Sasieni, A. Castanon, and J. Cuzick Screening and adenocarcinoma of the cervix Int J Cancer 125 2009 525 529
6. F. Bray, B. Carstensen, H. Møller, M. Zappa, M. Primic Zakelj, and G. Lawrence Incidence trends of adenocarcinoma of the cervix in 13 European countries Cancer Epidemiol Biomarkers Prev 14 2005 2191 2199
7. INK4a Is a useful marker for the diagnosis of Adenocarcinoma of the cervix uteri and its precursors Am J Surg Pathol 27 2003 187 193
8. G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, and A. Del Mistro Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial Lancet Oncol 11 2010 249 257
9. P.E. Castle, and H.A. Katki Benefits and risks of HPV testing in cervical cancer screening Lancet Oncol 11 2010 214 215
10. S. Costa, G. Negri, M. Sideri, D. Santini, G. Martinelli, and S. Venturoli Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix Gynecol Oncol 106 2007 170 176
11. K. Syrjänen HPV and cervical adenocarcinoma K. Syrjänen, S. Syrjänen, Papillomavirus infections in human pathology 2000 Wiley New York 189 206 [chapter 8]
12. G.D. Zielinski, P.J. Snijders, L. Rozendaal, N.F. Daalmeijer, E.K. Risse, and F.J. Voorhorst The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix J Pathol 201 2003 535 543
13. X. Castellsagué, M. Díaz, S. de Sanjosé, N. Muñoz, R. Herrero, and S. Franceschi Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention J Natl Cancer Inst 98 2006 303 315
14. E. Carico, F. Fulciniti, M.R. Giovagnoli, N.S. Losito, G. Botti, and G. Benincasa Adhesion molecules and p16 expression in endocervical adenocarcinoma Virchows Arch 455 2009 245 251
15. W.J.K. Levenback, A. Malpica, M. Morris, T. Burke, and M.F. Mitchell Adenocarcinoma in situ of the cervix: significance of cone biopsy margins Obstet Gynecol 88 1996 82 86
16. G.M. Muntz Can cervical adenocarcinoma in situ be safely managed by conizations alone Gynecol Oncol 61 1996 301 303
17. W.P. Soutter, D. Haidopoulos, R.J. Gornall, G.A. McIndoe, J. Fox, and W.P. Mason Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG 108 2001 1184 1189
18. F. Smedts, F.C. Ramaekers, and A.H. Hopman The two faces of cervical adenocarcinoma in situ Int J Gynecol Pathol 29 2010 378 385
19. L.T. Gien, M.C. Beauchemin, and G. Thomas Adenocarcinoma: a unique cervical cancer Gynecol Oncol 116 2010 140 146
20. ACOG Practice Bulletin Clinical management guidelines for obstetrician-gynaecologist. Management of abnormal cervical cytology and histology Obstet Gynecol 106 2005 645 663
21. P. Bryson, R. Stulberg, L. Shepherd, K. McLelland, and J. Jeffrey Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS? Gynecol Oncol 93 2004 465 468
22. A.W. Kennedy, and C.V. Biscotti Further study of the management of cervical adenocarcinoma in situ Gynecol Oncol 86 2002 361 364
23. R.J. Zaino Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix Int J Gynecol Pathol 21 2002 314 326
24. A.A. El-Ghobashy, A.M. Shaaban, J. Herod, and C.S. Herrington The pathology and management of endocervical glandular neoplasia Int J Gynecol Cancer 5 2005 583 592
25. P.J. Diggle, K.-Y. Liang, and S.L. Zeger Analysis of longitudinal data 1st ed. 1994 Oxford University Press Oxford
26. S.F.M. Derchain, S.H. Rabelo-Santos, L.O. Sarian, L.C. Zeferino, E.R. de Olivera Zambeli, and M.C. do Amaral Westin Human Papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap semars Gynecol Oncol 95 2004 618 623
27. N.S. Goldstein, and A. Mani The status and distance of cone biopsy margins as a predictor of excision adequacy for endocervical adenocarcinoma in situ Am J Clin Pathol 109 1998 727 732
28. M. Bertrand, G.M. Lickrish, and T.J. Colgan The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment Am J Obstet Gynecol 157 1987 21 25
29. M.T. McHale, T.D. Le, R.A. Burger, M. Gu, J.L. Rutgers, and B.J. Monk Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix Obstet Gynecol 98 2001 726 731
30. D.D. Im, L.R. Duska, and N.B. Rosenheim Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease Gynecol Oncol 59 1995 179 182